S100A4 and Familial prostate cancer: In this regard, the S100A4 inhibitor niclosamide is currently in phase II clinical trial for metastatic colorectal cancer (NCT02519582) and prostate cancer (NCT02807805) and has completed phase I trial for prostate cancer (NCT02532114) [43,44,45].